SAMRC PrEPVacc HIV Prevention Vaccine clinical trial in full swing

From the SAMRC press release:

Cape Town | While South Africa and the rest of the world continue to make encouraging progress in their response to the COVID-19 pandemic, the development of a safe and effective HIV prevention vaccine also remains critical for global health – something the South African Medical Research Council has not lost sight of.

Through its HIV Prevention Research Unit (HPRU), the SAMRC in October this year enrolled the first participant for the groundbreaking PrEPVacc Trial at its Verulam Clinical Research Site in Durban, KwaZulu-Natal. This historic enrollment brought the number of sites enrolling into the PrEPVacc study to four – including sites in Masaka, Uganda; Mbeya and Dar es Salaam in Tanzania.

To read the full release visit the SAMRC site here